

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

DIVISION OF CORPORATION FINANCE

August 11, 2020

Corey N. Fishman President and Chief Executive Officer Iterum Therapeutics plc Block 2 Floor 3, Harcourt Centre Harcourt Street Dublin 2, Ireland

> Re: Iterum Therapeutics plc Form 10-K for the fiscal year ended December 31, 2019 Filed March 12, 2020 File No. 001-38503

Dear Mr. Fishman:

We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Sincerely,

Division of Corporation Finance Office of Life Sciences